Literature DB >> 12749733

Management of patients with recurrent vulvovaginal candidiasis.

Jack D Sobel1.   

Abstract

Recurrent vulvovaginal candidiasis (RVVC) is by no means uncommon and is a source of considerable physical discomfort in addition to serving as a major therapeutic challenge. The syndrome is multifactorial in aetiology and hence management strategies must recognise the complex aetiological pathways. Many women receiving the misplaced diagnosis of RVVC have a variety of other infectious and non-infectious entities presenting with identical symptoms. Hence the first step in management is confirming the diagnosis of RVVC including microbial confirmation and species identification. Efforts should be made to identify and correct a causal mechanism. Maintenance suppressive azole antifungal regimens are highly effective in controlling symptoms, although cure is less common. Further advances in achieving higher cure rates await the availability of non-azole fungicidal agents.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12749733     DOI: 10.2165/00003495-200363110-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  23 in total

1.  Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS.

Authors:  P Schuman; L Capps; G Peng; J Vazquez; W el-Sadr; A I Goldman; B Alston; C L Besch; A Vaughn; M A Thompson; M N Cobb; T Kerkering; J D Sobel
Journal:  Ann Intern Med       Date:  1997-05-01       Impact factor: 25.391

2.  Frequency and response to vaginal symptoms among white and African American women: results of a random digit dialing survey.

Authors:  B Foxman; J V Marsh; B Gillespie; J D Sobel
Journal:  J Womens Health       Date:  1998-11       Impact factor: 2.681

3.  Recurrent genital candidosis in women and the effect of intermittent prophylactic treatment.

Authors:  F Davidson; R F Mould
Journal:  Br J Vener Dis       Date:  1978-06

4.  The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women.

Authors:  J D Sobel; S E Ohmit; P Schuman; R S Klein; K Mayer; A Duerr; J A Vazquez; A Rampalo
Journal:  J Infect Dis       Date:  2001-01-15       Impact factor: 5.226

5.  Recurrent allergic vulvovaginitis: treatment with Candida albicans allergen immunotherapy.

Authors:  D Rigg; M M Miller; W J Metzger
Journal:  Am J Obstet Gynecol       Date:  1990-02       Impact factor: 8.661

Review 6.  Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations.

Authors:  J D Sobel; S Faro; R W Force; B Foxman; W J Ledger; P R Nyirjesy; B D Reed; P R Summers
Journal:  Am J Obstet Gynecol       Date:  1998-02       Impact factor: 8.661

7.  Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy.

Authors:  J D Sobel
Journal:  N Engl J Med       Date:  1986-12-04       Impact factor: 91.245

8.  Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis.

Authors:  E Hilton; H D Isenberg; P Alperstein; K France; M T Borenstein
Journal:  Ann Intern Med       Date:  1992-03-01       Impact factor: 25.391

9.  Fluconazole levels in plasma and vaginal secretions of patients after a 150-milligram single oral dose and rate of eradication of infection in vaginal candidiasis.

Authors:  E T Houang; O Chappatte; D Byrne; P V Macrae; J E Thorpe
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

10.  Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates.

Authors:  M E Lynch; J D Sobel
Journal:  J Med Vet Mycol       Date:  1994
View more
  10 in total

1.  A Combination Fluorescence Assay Demonstrates Increased Efflux Pump Activity as a Resistance Mechanism in Azole-Resistant Vaginal Candida albicans Isolates.

Authors:  Somanon Bhattacharya; Jack D Sobel; Theodore C White
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

2.  Effect of pH on in vitro susceptibility of Candida glabrata and Candida albicans to 11 antifungal agents and implications for clinical use.

Authors:  Claire S Danby; Dina Boikov; Rina Rautemaa-Richardson; Jack D Sobel
Journal:  Antimicrob Agents Chemother       Date:  2012-01-09       Impact factor: 5.191

Review 3.  [Mycotic infections of the anogenital region].

Authors:  P Mayser; W Hort; S Pflieger-Bruss
Journal:  Hautarzt       Date:  2005-06       Impact factor: 0.751

4.  Time course of global gene expression alterations in Candida albicans during infection of HeLa cells.

Authors:  Yi-Bing Lan; Yi-Zhou Huang; Fan Qu; Juan-Qing Li; Lin-Juan Ma; Jie Yan; Jian-Hong Zhou
Journal:  Bosn J Basic Med Sci       Date:  2017-05-20       Impact factor: 3.363

Review 5.  Local treatment of vulvovaginal candidosis : general and practical considerations.

Authors:  José das Neves; Eugénia Pinto; Branca Teixeira; Gustavo Dias; Patrocínia Rocha; Teresa Cunha; Bárbara Santos; Maria H Amaral; Maria F Bahia
Journal:  Drugs       Date:  2008       Impact factor: 9.546

6.  A Novel 1,3-Beta-d-Glucan Inhibitor, Ibrexafungerp (Formerly SCY-078), Shows Potent Activity in the Lower pH Environment of Vulvovaginitis.

Authors:  E L Larkin; L Long; N Isham; K Borroto-Esoda; S Barat; D Angulo; S Wring; M Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

7.  Highly-cited estimates of the cumulative incidence and recurrence of vulvovaginal candidiasis are inadequately documented.

Authors:  Sujit D Rathod; Patricia A Buffler
Journal:  BMC Womens Health       Date:  2014-03-10       Impact factor: 2.809

Review 8.  Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms.

Authors:  Patrick Van Dijck; Jelmer Sjollema; Bruno P Cammue; Katrien Lagrou; Judith Berman; Christophe d'Enfert; David R Andes; Maiken C Arendrup; Axel A Brakhage; Richard Calderone; Emilia Cantón; Tom Coenye; Paul Cos; Leah E Cowen; Mira Edgerton; Ana Espinel-Ingroff; Scott G Filler; Mahmoud Ghannoum; Neil A R Gow; Hubertus Haas; Mary Ann Jabra-Rizk; Elizabeth M Johnson; Shawn R Lockhart; Jose L Lopez-Ribot; Johan Maertens; Carol A Munro; Jeniel E Nett; Clarissa J Nobile; Michael A Pfaller; Gordon Ramage; Dominique Sanglard; Maurizio Sanguinetti; Isabel Spriet; Paul E Verweij; Adilia Warris; Joost Wauters; Michael R Yeaman; Sebastian A J Zaat; Karin Thevissen
Journal:  Microb Cell       Date:  2018-06-14

9.  Candida vaginitis among symptomatic pregnant women attending antenatal clinics in Mwanza, Tanzania.

Authors:  Martha F Mushi; Amani Mmole; Stephen E Mshana
Journal:  BMC Res Notes       Date:  2019-11-27

10.  Identification of sulfur components enhancing the anti-Candida effect of Lactobacillus rhamnosus Lcr35.

Authors:  Caroline Dausset; Stéphanie Bornes; Sylvie Miquel; Nathalie Kondjoyan; Magaly Angenieux; Laurence Nakusi; Philippe Veisseire; Elina Alaterre; Luis G Bermúdez-Humarán; Philippe Langella; Erwan Engel; Christiane Forestier; Adrien Nivoliez
Journal:  Sci Rep       Date:  2020-10-13       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.